There were no significant differences in age, serum levels of alanine aminotransferase, the platelet count, Child–Pugh score, first treatment regimen, and tumor-related factors, such as tumor makers (AFP and PIVKA-II) and clinical cancer stage, between the groups with and without DM. This evidence concerns the gene GPT and neoplasm.